BSX · 10-Q · 2026Q2 · Full report

Competition and Market Share

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 23 · Surprise 24

Boston Scientific said increased competition in its Electrophysiology business unit affected Cardiovascular sales in both the second quarter and first six months of 2026. The company also reported a deceleration in certain WATCHMAN™ procedures, creating an additional demand headwind within Cardiovascular. These pressures partially offset otherwise strong growth from the Farapulse™ PFA System and other cardiovascular franchises.

Key facts

• Cardiovascular reported net sales growth in Q2 and the first six months of 2026 was primarily driven by the coronary therapies franchise led by the AGENT™ Drug-Coated Balloon and Electrophysiology led by the Farapulse™ PFA System; net sales were impacted by increased competition within Electrophysiology and a deceleration of certain WATCHMAN™ procedures. source